Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-02-18
1997-05-27
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514385, 514396, A61K 31415
Patent
active
056332742
ABSTRACT:
The Applicant has identified a particular class of imidazoles that inhibit nonprostate cancer cell proliferation. These imidazoles can be used to beneficially treat a variety of cancers. The imidazoles can be administered in a variety of formulations, including long-term sustained release implants and anti-cancer cocktails.
REFERENCES:
patent: 3678030 (1972-07-01), Yamazaki et al.
patent: 3901908 (1975-08-01), Fitzi et al.
patent: 3940486 (1976-02-01), Fitzi
patent: 3965112 (1976-06-01), White et al.
patent: 4073922 (1978-02-01), Wyburn-Mason
patent: 4119723 (1978-10-01), Wyburn-Mason
patent: 4218449 (1980-08-01), Wyburn-Mason
patent: 4491588 (1985-01-01), Rosenburg et al.
patent: 4569935 (1986-02-01), Rosenberg et al.
patent: 4657925 (1987-04-01), Horn
patent: 4758580 (1988-07-01), Numasaki et al.
patent: 4837333 (1989-06-01), Manley et al.
patent: 4886818 (1989-12-01), Numasaki et al.
patent: 4916118 (1990-04-01), Fidler et al.
patent: 4942162 (1990-07-01), Rosenburg et al.
patent: 5001134 (1991-03-01), Ferrand et al.
patent: 5023090 (1991-06-01), Levin
patent: 5057530 (1991-10-01), Barner et al.
patent: 5059590 (1991-10-01), Ueda et al.
patent: 5132315 (1992-07-01), Kohn et al.
patent: 5273992 (1993-12-01), Brugnara et al.
patent: 5326790 (1994-07-01), Thornfeldt
patent: 5358959 (1994-10-01), Halperin et al.
patent: 5385938 (1995-01-01), Yu et al.
patent: 5389677 (1995-02-01), Yu et al.
Carter et al; Chemotherapy of Cancer, John Wiley & Sons, pp. 361-365. (1981).
Rosenberg, E.W. et al., Improvement of Psoriasis of the Scalp with Ketaconazole; Arch. Dermatol, Jun. 1982; 370-371.
Shelnitz, L.S. et al., Etretinate Therapy for Generalized Pustular Psoriasis in Children; Arch. Dermatol. Feb. 1987; pp. 230-233.
Lee, R.E. et al., Interleukin 2 and Psoriasis; Arch. Dermatol. V.124, Dec. 1988; pp. 1811-1815.
Going, S., The Treatment of Psoriasis; the Practitioner, Jul. 1988, v. 232; pp. 824-827.
Al-Ghamdi, F. et al., Dramatic Effect of Cyclosporin in Generalized Pustular Psoriasis-The Effective Dose; Saudi Med.J.v.13 No.5 (1991).
Dixon, B.S. et al., Histidine Regulation of Cyclic AMP Metabolism in Cutlured Renal Epithelial LLC-PK1 Cells; J. Biol. Chem., v. 265, No. 2, Jan. 15, 1990; pp. 760-766.
Fisher, J. et al., Therapeutic Failures with Miconazole; Antimicrobial Agents and Chemotherapy; Jun. 1978; pp. 965-968.
Coskey, R.J., Dermatologic Therapy; 1993; J. Of the American Academy of Dermatology; Nov. 1994, pp. 764-774.
Heel, R.C. et al., Miconazole; A Preliminary Review of its Therapeutic Efficacy in Systemic Fungal Infections, (1980), 7-30, Drugs 19.
Ritter, W. et al., Pharmacokinetic Fundamentals of Vaginal Treatment with Clotrimazole; (1982); 37-42; Chemotherapy 28.
Ritter, W.; Pharmacokinetic Fundamentals of Vaginal Treatment with Clotrimazole; Am J. Obstet. Gynecol., 152:945-947 (1985).
Duhm, B. et al., The Pharmacokinetics of Clotrimazole 14C; (Jul. 1974); 13-16; Postgraduate Medical Journal 50.
F. Delbarre, On the Possible Anti-Rheumatic Effects (Immuno-effector ?) of Imidazole Derivatives (levamisole, clortrimazole, niridazole), Biomedicine, 1977, 27, 97-98.
Knud Lund-Olesen, Clotrimzaole, Plasma Cortisol and Rheumatoid Arthritis; Current Therapeutic Research, vol. 21, No. 5, May, 1977 704-706.
W. Dennison et al., A Double Blind Placebo Controlled Trial of Low Dose Clotrimazole in Rheumatoid Arthritis; The Journal of Rheumatology, 1990; 17;8; 1003-1007.
Wojtulewski et al., Clotrimazole in rheumatoid Arthritis; Annals of the Rheumatic Diseases; 1980, 39, 469-572.
Carter et al. Chemotherapy of Cancer, Second Edition 361-365 (1982).
Najid et al. Comparative Studies of Steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell . . . cytometric DNA analysis; Chemical Abstracts, vol. 106, 1987; 116:187584x.
Sawyer, P. et al., Clotrimazole; A Review of its Antifungal Activity and Therapeutic Efficacy; Drugs 9:424-447; ( 1975).
Ohnishi, S.T. et al., Inhibition of the In Vitro Formation of Dense Cells and of Irreversibly Sickled Cells by Charybdotoxin, A Specific Inhibitor of Calcium-Activated Potassium Efflux; 199-203; Biochemica et Biophysica Acta 1010 (1989).
Wolff, D. et al. Charybdotoxin Blocks with High Affinity the Ca-Activated K+ Channel of HB A and Hb S Red Cells; Individual Differences In the Number of Channels; J. Membrane Biol. 106.243-252 (1988).
Brugnara, C. et al., Ca2+-activated K+ Transport in Erythrocytes J. Biol. Chem.; 1993; 8760-8768.
De Franceschi, L.; Treatment with Oral Clotrimazole Blocks Ca2+-activated K+ Transport and Reverses Erythrocyte Dehydration in Transgenic SAD Mice; J. Clin. Invest. 93:1670-1676; Apr. 1994.
Brugnara, C. et al., Inhibition of Ca2+-dependent K+ Transport and Cell Dehydration in Sickle Erythrocytes by Clotrimazole and Other Imidazole Derivatives; J. Clin. Invest. 92:520-526; Jul. 1993.
Society of General Physiologists 48th Annual Symposium; Ion Channels and Genetic Diseases; Sep. 8, 1994.
Muhktar, H. et al., Clotrimazole, an Inhibitor of Epidermal Benzo(a)pyrene Metabolism and DNA Binding and Carcinogenicity of the Hydrocarbon; Cancer Res., 44:4283-4240, Oct. 1984.
Calmodulin Antagonists in Psoriasis; SCRIP No. 1797, Feb. 23, 1993 p. 23.
Fogue-Lafitte et al. Effects of ketoconazole on the proliferation; Cancer Cell Res. 52:6827-6831 (1992).
Tzanakakis et al., Inhibition of Hepatic Metastisis, Cancer, 65:446-451 (1990).
Nardone, et al., Ketoconazole; A Thromboxane Synthetase; J. Surgical Res., 44: 425-429 (1988).
Chemical Abstracts: CA 106: 209231c (1987).
Chemical Abstracts: CA 101:183620 (1984).
Chemical Abstracts: CA 116: 187584x (1992).
Marie Elisabeth Forgue-Lafitte, Anne-Marie Coudray, Dominique Fagot, and Jan Mester--"Effects of Ketoconazole on the Proliferation and Cell Cycle of Human Cancer Cell Lines", Cancer Research 52, 6827-6831, Dec. 15, 1992.
George N. Tzanakakis, MD., Kailash C. Agarwal, PhD., Michael P. Vezeridis, MD.--"Inhibition of Hepatic Metastasis From a Human Pancreatic Adenocarcinoma (RWP-2) in the Nude Mouse" by Prostacyclin, Forskolin, and Ketoconzzole, Cancer, vol. 65, Feb. 1, 1990.
Patricia A. Nardone, M.D., Gus J. Slotman, M.D., and Michael P. Vezeridis, M.D., "Ketoconazole: A Thromboxane Synthetase and 5-Lipoxygenase Inhibitor with Antimetastatic Activity in B16-F10 Melanoma", Journal of Surgical Research 44,425-429 (1988).
W. Wouters et al.; Effects of Liarozole, a New Antitumoral Compound, on Retinoic Acid-induced Inhibition of Cell Growth and on Retinoic Acid Metabolism in MCF-7 Human Breast Cancer Cells; May 15, 1992; pp. 2841-2846; Cancer Research 52.
A. Najid and M. Ratinaud; Comparative Studies of Steroidogenesis Inhibitors (Econazole, Ketoconazole) on Human Breast Cancer MCF-7 Cell Proliferation by Growth Experiments, Thymidine Incorporation and Flow Cytometric DNA Analysis; 1991; pp. 385-390; Tumori 77.
N. Burres et al.; Antitumor Activity and Biochemical Effects of Topsentin; 1991; pp. 745-751; Biochemical Pharmacology.
T. Nordstrom et al.; Mitosis-Arresting Effect of the Calcium Channel Inhibitor SK&F 96365 on Human Leukemia Cells; 1992; pp. 487-494; Experimental Cell Research.
A. Galeano et al.; Antitumor Activity of Some Ruthenium Derivatives in Human Colon Cancer Cell Lines in vitro; 1992; pp. 821-824; Drug Res.
Brugnara Carlo
Halperin Jose
Criares Theodore J.
Gates Edward R.
President and Fellows of Harvard College
LandOfFree
Cancer treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2329394